Cytokinetics (CYTK) News Today $34.38 +1.18 (+3.55%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$34.28 -0.10 (-0.29%) As of 06/13/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CYTK Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Harbor Capital Advisors Inc. Grows Position in Cytokinetics, Incorporated (NASDAQ:CYTK)Harbor Capital Advisors Inc. increased its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 17.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 53,113 shares of the biopharmaceutical company'sJune 12 at 4:51 AM | marketbeat.comCytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorganJune 11 at 9:25 PM | insidermonkey.comAnalysts Set Expectations for Cytokinetics FY2026 EarningsJune 11 at 2:39 AM | americanbankingnews.comCytokinetics Calls for DonationsJune 10, 2025 | baystreet.caCantor Fitzgerald Forecasts Cytokinetics FY2026 EarningsCytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Cytokinetics in a report released on Monday, June 9th. Cantor Fitzgerald analyst C. Gould expects that the biopharmaceutical company will post earninJune 10, 2025 | marketbeat.comCytokinetics Announces Call For Proposals For Annual Corporate Giving ProgramJune 10, 2025 | globenewswire.comJPMorgan Chase & Co. Has Lowered Expectations for Cytokinetics (NASDAQ:CYTK) Stock PriceJune 10, 2025 | americanbankingnews.comCytokinetics (NASDAQ:CYTK) Price Target Cut to $53.00 by Analysts at JPMorgan Chase & Co.JPMorgan Chase & Co. cut their target price on Cytokinetics from $71.00 to $53.00 and set an "overweight" rating for the company in a research note on Monday.June 9, 2025 | marketbeat.comRhumbline Advisers Lowers Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)Rhumbline Advisers lowered its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 2.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 373,855 shares of the biopharmaceutical coJune 9, 2025 | marketbeat.com329,231 Shares in Cytokinetics, Incorporated (NASDAQ:CYTK) Purchased by E. Ohman J or Asset Management ABE. Ohman J or Asset Management AB purchased a new position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 329,231 shares of the biopharmaceutical companyJune 6, 2025 | marketbeat.comRFG Advisory LLC Invests $1.29 Million in Cytokinetics, Incorporated (NASDAQ:CYTK)RFG Advisory LLC purchased a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 32,005 shares of the biopharmaceutical company's stock, valuedJune 6, 2025 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Director Sells $116,715.60 in StockCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) Director Edward M. Md Kaye sold 3,636 shares of Cytokinetics stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $32.10, for a total value of $116,715.60. Following the transaction, the director now owns 29,658 shares in the company, valued at approximately $952,021.80. This represents a 10.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.June 5, 2025 | marketbeat.comInsider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells 8,659 Shares of StockCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 8,659 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $32.04, for a total transaction of $277,434.36. Following the completion of the transaction, the executive vice president now owns 52,028 shares in the company, valued at approximately $1,666,977.12. This trade represents a 14.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.June 5, 2025 | marketbeat.comStock Traders Buy High Volume of Call Options on Cytokinetics (NASDAQ:CYTK)Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) saw some unusual options trading on Wednesday. Stock traders bought 5,137 call options on the company. This represents an increase of 96% compared to the typical volume of 2,622 call options.June 4, 2025 | marketbeat.comInsider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK)June 3, 2025 | gurufocus.comCytokinetics, Incorporated (NASDAQ:CYTK) CEO Sells $156,100.00 in StockCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) CEO Robert I. Blum sold 5,000 shares of Cytokinetics stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $31.22, for a total value of $156,100.00. Following the transaction, the chief executive officer now owns 408,108 shares of the company's stock, valued at $12,741,131.76. This represents a 1.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.June 3, 2025 | marketbeat.comMirador Capital Partners LP Buys 33,489 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)Mirador Capital Partners LP raised its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 51.0% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 99,125 shares of the biopharmaceutical company's stock after acquiring an additional 33,June 2, 2025 | marketbeat.comCetera Investment Advisers Decreases Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)Cetera Investment Advisers lowered its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 82.5% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 4,551 shares of the biopharmaceutical company's stock after selling 21,48June 2, 2025 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Recommendation of "Moderate Buy" by BrokeragesCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the sixteen analysts that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation, eleven have given a bJune 1, 2025 | marketbeat.comJefferies Financial Group Inc. Has $593,000 Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)Jefferies Financial Group Inc. decreased its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 98.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,600 sharesMay 31, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Lowers Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 52.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutionaMay 31, 2025 | marketbeat.comMizuho Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $84.00Mizuho dropped their price objective on shares of Cytokinetics from $103.00 to $84.00 and set an "outperform" rating on the stock in a research note on Thursday.May 30, 2025 | marketbeat.comCytokinetics to Participate in the Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comStifel Nicolaus Sticks to Its Buy Rating for Cytokinetics (CYTK)May 29, 2025 | theglobeandmail.comNuveen Asset Management LLC Trims Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)Nuveen Asset Management LLC reduced its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 2.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 373,229 shares of the biopharmaceutical company's stock after selling 9,947 shares during the perioMay 26, 2025 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Shares Purchased by Two Sigma Advisers LPTwo Sigma Advisers LP increased its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 5.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 226,400 shares of the biopharmaceuticaMay 25, 2025 | marketbeat.comCytokinetics at RBC Conference: Strategic Insights on Drug DevelopmentMay 23, 2025 | uk.investing.comCytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Zimmer Partners LPZimmer Partners LP lessened its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 50.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,000 shares of the biopharmaceutical comMay 23, 2025 | marketbeat.comProShare Advisors LLC Acquires 9,620 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)ProShare Advisors LLC increased its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 28.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 43,299 shares of the biopharmaceutical company's stock after acquiring an additional 9,62May 23, 2025 | marketbeat.com329,136 Shares in Cytokinetics, Incorporated (NASDAQ:CYTK) Bought by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. purchased a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 329,136 shares of tMay 22, 2025 | marketbeat.comTeza Capital Management LLC Takes Position in Cytokinetics, Incorporated (NASDAQ:CYTK)Teza Capital Management LLC bought a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 9,488 shares of thMay 22, 2025 | marketbeat.comBNP Paribas Financial Markets Trims Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)BNP Paribas Financial Markets reduced its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 38.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,647 shares of the biMay 22, 2025 | marketbeat.comVestal Point Capital LP Has $110.54 Million Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)Vestal Point Capital LP increased its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 56.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,350,000 shares of the biopharmaceutical comMay 21, 2025 | marketbeat.com47,383 Shares in Cytokinetics, Incorporated (NASDAQ:CYTK) Purchased by Tema Etfs LLCTema Etfs LLC purchased a new position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 47,383 shares of the biopharmaceutical company's stock, valuMay 20, 2025 | marketbeat.comRafferty Asset Management LLC Trims Stock Position in Cytokinetics, Incorporated (NASDAQ:CYTK)Rafferty Asset Management LLC lowered its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 22.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 167,935 shares of the biopharmaceutical company'sMay 20, 2025 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) is Sarissa Capital Management LP's 4th Largest PositionSarissa Capital Management LP trimmed its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 24.9% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 833,799 shares of the biopharmaceutical company's stock after selling 276,201 shares duriMay 19, 2025 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Position Lessened by Jefferies Financial Group Inc.Jefferies Financial Group Inc. trimmed its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 98.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,600 sharMay 19, 2025 | marketbeat.comCytokinetics presents additional data related to AficamtenMay 18, 2025 | msn.comCytokinetics Inc (CYTK) Unveils New Data on Aficamten's Efficacy in HCM Patients | CYTK stock newsMay 18, 2025 | gurufocus.comCytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 CongressMay 18, 2025 | globenewswire.comCantor Fitzgerald Upgrades Cytokinetics (NASDAQ:CYTK) to "Strong-Buy"Cantor Fitzgerald raised Cytokinetics to a "strong-buy" rating in a research report on Tuesday.May 17, 2025 | marketbeat.comCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 16, 2025 | globenewswire.comCytokinetics, Incorporated (NASDAQ:CYTK) Director Muna Bhanji Sells 1,454 SharesMay 16, 2025 | insidertrades.comCytokinetics' (CYTK) Buy Rating Reiterated at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $72.00 price target on shares of Cytokinetics in a report on Wednesday.May 16, 2025 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Janus Henderson Group PLCJanus Henderson Group PLC cut its stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 10.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,024,417 shares of the biopharmaceutical coMay 16, 2025 | marketbeat.comOrbimed Advisors LLC Increases Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)Orbimed Advisors LLC increased its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 106.5% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,584,005 shares of the biopharmaceutical company's stock after purchMay 15, 2025 | marketbeat.comCytokinetics to Host Symposium on Contemporary Landscapes in Muscle BiologyMay 15, 2025 | globenewswire.comAmeriprise Financial Inc. Raises Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)Ameriprise Financial Inc. increased its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 38.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 752,401 shares of the biopharmaMay 15, 2025 | marketbeat.comDimensional Fund Advisors LP Trims Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)Dimensional Fund Advisors LP lowered its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 21.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 94,124 shares of the biopharmaceutical company's stock after sellMay 15, 2025 | marketbeat.comIntegral Health Asset Management LLC Acquires 250,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)Integral Health Asset Management LLC lifted its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 33.3% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,000,000 shares of the biopharmaceutical company's stock afterMay 14, 2025 | marketbeat.com Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address CYTK Media Mentions By Week CYTK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYTK News Sentiment▼0.410.88▲Average Medical News Sentiment CYTK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYTK Articles This Week▼1410▲CYTK Articles Average Week Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Genmab A/S News Intra-Cellular Therapies News Dr. Reddy's Laboratories News Moderna News Ascendis Pharma A/S News Viatris News Qiagen News Blueprint Medicines News Roivant Sciences News Revolution Medicines News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CYTK) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
